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Abstract
Methods for susceptibility testing of Aspergillus are developed and validated by the European Committee on Antibiotic Susceptibility Testing
Subcommittee on Antifungal Susceptibility Testing. Breakpoints for phenotypic antimicrobial susceptibility testing have been determined by
breakpoint committees and as part of regulatory processes for the approval of new drugs. Dosages, pharmacokinetics, resistance
mechanisms, MIC distributions, pharmacodynamics and epidemiological cut-off values are used in the breakpoint-setting process. Clinical
breakpoints are for everyday use in the clinical laboratory to advise on patient therapy. Resistance in Aspergillus fumigatus has been
increasingly reported since standards became available.
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Antifungal Susceptibility Testing
Invasive fungal infections have increased over the past two
decades causing formidable morbidity and mortality among
immunocompromised hosts [1]. The frequency of nosocomial
fungal infections has also increased among cancer, organ
transplant, burn and surgical patients. Due to the life-threat-
ening nature of these infections and reports of drug resistance,
susceptibility testing has become important [2]. Testing
methods include broth microdilution for yeasts and moulds
according to the European Committee on Antibiotic Suscep-
tibility Testing (EUCAST) group and Clinical and Laboratory
Standards Institute (CLSI) [3,4].
According to EUCAST methodology, reading the MIC
endpoint for moulds [5] differs from the criteria established
for yeasts [6]. Amphotericin B, itraconazole, posaconazole and
voriconazole endpoints are all determined at the lowest
concentration that prevents discernable growth or in other
words, the ﬁrst clear well [7]. The candins do not provide a
MIC but rather a MEC or minimum effective concentration [5].
The candins attack the growing tips of the hyphae resulting in
aberrant, stubby growth of the hyphae. This aberrant growth is
easily visualized as the hyphae cluster within the well in clumps.
Microscopic examination will display obviously distorted
hyphae.
The EUCAST broth microdilution standard [3] differs from
CLSI [4] in the usage of microplate well shape (ﬂat and round
bottom), content of sugar of the RPMI broth (2% and 0.2%
dextrose), inoculum concentrations (105 CFU/mL adjusted by
conidial counting and 104 CFU/mL adjusted by spectropho-
tometer) and ﬁnal DMSO concentration (0.5% and 1%) [3,4].
There are a variety of commercial products such as Etest,
Vitek 2, Sensititre YeastOne panel and disk diffusion assays,
but most of these tests are not validated for Aspergillus
antifungal susceptibility testing. Numerous in vitro factors such
as media, buffer, inoculum, incubation and endpoint criteria
can affect results signiﬁcantly [8,9]. Difﬁculties in MIC reading
have been reported for the echinocandins and Aspergillus spp.
The use of standard RPMI-1640 medium has been suggested, as
lot variability associated with antibiotic medium 3 limits its use
[10]. By contrast, others recommend the use of antibiotic
medium 3 for caspofungin testing [11]. Incubation of plates in
micro-aerophilic conditions makes the endpoint easier to read
[12]. Most methods are therefore reported to provide at best
an estimation of the MIC value within 3 twofold dilution steps.
To check the performance with respect to the quality and
consistency of reagents, media, inoculum and procedure, the
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use of quality control strains is necessary for each testing.
EUCAST recommends A. fumigatus ATCC 204305, A. ﬂavus
ATCC 204304, A. fumigatus F 6919, A. ﬂavus CM 1813,
C. parapsilosis ATCC 22019 (read after 18–24 h) or C. krusei
ATCC 6258 (read after 18–24 h) [5]. In vitro factors which
inﬂuence MIC results are shown in Table 1. Performance is
satisfactory if MIC values obtained are within the quality
control speciﬁcations provided. MIC values may not necessar-
ily correlate with in vivo efﬁcacy noted. However, the most
important role of testing is detecting resistance, which means
determining agents that may not work.
Microbiologists and clinicians are still faced with the
challenge of interpreting the results of in vitro antifungal
susceptibility tests. MIC values do not always directly associate
with response to antifungal therapy. The discordance between
in vivo and in vitro data is illustrated by the 90–60 rule, which
maintains that infections caused by susceptible strains respond
to appropriate therapy in 90% of cases, whereas infections
caused by resistant strains respond in 60% of cases [13]. The
most important factors associated with poor outcome are
negative host status [1], delay of early diagnosis [14], a lack of
adequate antifungal therapy [15] and infection with drug-resis-
tant pathogens [2,16].
The deﬁnitions for antifungal resistance can be microbiolog-
ical, clinical or a composite of both. Microbiological resistance is
given when fungi grow at drug concentrations higher than the
range seen for wild-type strains. For clinical resistance, the
infecting organism is inhibited by a drug concentration that is
not achieved safely with normal dosing [16].
The Role of ECOFFs and CBP
Dealing with MICs in the clinical routine warrants consider-
ation of epidemiological cut-off values (ECOFF) and/or clinical
breakpoints (CBP) [7]. EUCAST and CLSI both set up ECOFFs
and CBPs for various drug–bug combinations [7,17]. ECOFFs
are estimated by visual inspection or statistical calculation [18]
and are not changed by sampling, time, source (human, animal
and environmental) and geographical origin. ECOFFs are used
in CBP development and as a sensitive indicator of resistance
development in surveillance studies. CBPs are used to indicate
isolates that are likely to respond to treatment with a given
antifungal agent administered at the approved dosing regimen.
There is no deﬁnitive relationship between CBPs and ECOFFs.
ECOFFs discriminate the wild-types strains from acquired
resistance mechanisms if drugs display a bimodal MIC distri-
bution; in other words, deﬁne the upper limit of wild-type MIC
distributions showing strains with no acquired resistance
mechanisms [5,14]. CBP should be selected to optimize the
detection of non-wild-type strains of individual species, should
not divide wild-type distributions of important target species,
and should be species speciﬁc. CBPs are used in clinical
microbiology laboratories to categorize microorganisms as
clinically susceptible (S), intermediate (I) or resistant (R)
dependent on the quantitative antimicrobial susceptibility as
indicated by the MIC value determined in a well-deﬁned
standard test system. The laboratory report, with the desig-
nations of S, I or R for each antimicrobial agent, provides
guidance to clinicians with respect to the potential use of
antifungals in the treatment of patients, and CBP should
therefore distinguish between patients that are likely or
unlikely to respond to treatment. Presently, we lack CBP for
most drug–bug combinations.
European Committee on Antibiotic Susceptibility Testing
breakpoints (ECOFFs) of A. fumigatus and A. niger for ampho-
tericin B were R >2 mg/L, of A. fumigatus, A. ﬂavus, A. nidulans
and A. terreus for itraconazole were R >2 mg/L, and of
A. fumigatus for posaconazole and voriconazole were
R >0.25 mg/L and R >2 mg/L, respectively (see Table 2).
Clinical and Laboratory Standards Institute breakpoints
(ECOFFs) of A. fumigatus, A. ﬂavus A. niger and A. versicolor for
amphotericin B were R >2 mg/L, of A. fumigatus, A. ﬂavus,
A. terreus for itraconazole and voriconazole were >1 mg/L, of
A. niger and A. versicolor >2 mg/L, respectively, and of A. fu-
migatus, A. ﬂavus, A. terreus for posaconazole were >0.5 mg/L
and for caspofungin were >0.06 mg/L (see Table 2).
There are several important considerations in antifungal
susceptibility testing which need to be taken into account
for setting CBP. These consist of applying (i) standardized
methods, (ii) quality controls, (iii) MIC frequency distribution
for each species including the analysis of MIC values of
mutants whose mechanisms of resistance are known, (iv)
ECOFFs for each species, (v) mechanisms of resistance and
cross-resistance, (vi) PK/PD parameters, (vii) clinical out-




Pleomorphism; conidia vs. hyphae
Fungal growth may be aerobically but also anaerobically
Medium, pH and incubation temperature can affect growth and
pleomorphism
Drug-speciﬁc factors
Limited aqueous solubility of some agents
Partial inhibition of growth over a wide concentration range resulting in
trailing endpoints typically seen with azoles. No inhibition of growth typically
seen with echinocandins and Aspergillus
Buffer and pH effects on activity
Interaction with media components and buffer
Variables that inﬂuence results
Inoculum
Medium formulation and pH
Agar vs. broth
Type of buffer (MOPS vs. phosphate)
Temperature and duration of incubation
MIC endpoint reading
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come vs MICs according to species and alternative methods
[4,14].
Hereafter listed are relevant factors in setting breakpoints
for new antifungals and assessment of data according to
EUCAST procedure for harmonizing and deﬁning CBP (for
further information on the structure of EUCAST, see the
EUCAST website http://www.eucast.org:
1. The national similarities and differences regarding maximum
and minimum dosing, available formulations (oral, iv), clinical
indications and practices and target organisms.
2. Multiple MIC distributions of relevant species, collected in
the EUCAST wild-type distribution program (www.eucast.
org), are assessed and epidemiological cut-off values
(deﬁned as WT ≤X mg/L) determined.
3. Dose–effect relationships obtained in in vitro studies, animal
studies and humans (PK/PD data) are evaluated.
4. Modelling processes, such as Monte Carlo simulation, may
be used to assist the process of breakpoint setting.
5. Clinical data relating outcome to MIC values.
6. Breakpoints suggested by the national breakpoint commit-
tees are compared and discussed.
7. Consensus breakpoints are sought.
8. Resulting breakpoints are tested against each of the major
target species MIC distributions. This is to make sure that
the suggested EUCAST breakpoints do not divide the
wild-type distributions of major target species. This would
obviate a reproducible S, I and R categorization in the
laboratory. The ensuing breakpoints may therefore differ
between species.
9. The committee may refrain from setting breakpoints if the
species is considered a poor target for the drug (marked
by—in breakpoint tables) or there is insufﬁcient evidence
that the species is a good target for the drug (marked by IE
in breakpoint tables).
When is Antifungal Susceptibility Testing
Indicated?
Based on the various clinical experiences, antifungal suscep-
tibility testing could be performed for patient management
and/or to study fungal epidemiology. MIC testing is recom-
mended in the event that the fungus is isolated from deep
body sites from a patient under antifungal treatment, or in
case of therapeutic failure or of involvement of rare and/or
emerging species, or when that particular species are known
to be resistant or less susceptible to an agent [19–21]. In
addition, antifungal susceptibility testing is applied as moni-
toring tool for epidemiological studies [20,21]. Aspergillus
species are generally susceptible to the various antifungal
drugs; however, intrinsic and acquired resistance has been
documented [9,22–25]. Amphotericin B has limited activity
against A. terreus [26] and A. nidulans [27], while A. calidoustus
appears to be resistant to triazole compounds [28]. Further-
more, several species in the A. fumigatus complex (A. lentulus,
A. pseudoﬁsheri and A. fumigatiafﬁnis) appear to be intrinsically
resistant to azoles, and in the case of A. lentulus and
A. fumigatiafﬁnis, resistant to amphotericin B as well [29].
An increasing number of triazole resistant A. fumigatus has
been reported, especially from Europe. Cross-resistance
among those emerging A. fumigatus is evident. However,
from an epidemiological point of view, less is known about
the true prevalence of resistance in Aspergillus species
complex.
TABLE 2. Epidemiological cut-off values and their clinical relevance
Drug EUCAST CLSI Comments
Amphotericin B High MICs (>1 lg/mL) have been reported for A. terreus, Paeciliomyces lilacinus, Alternaria species, Mucorales species
MICs >1 may be species dependent
Non-WT amphotericin B MICs >1 lg/mL have been suggestive of clinical failure
A. fumigatus 2 2
A. ﬂavus 2 2
A. terreus IE 4
A. niger IE 2
Triazoles MICs are usually <2 lg/mL and higher MICs have been reported for A. calidoustus, A. lentulus and A. fumigatus
Azole cross-resistance has been reported
Non-WT azoles MICs >2 lg/mL have been observed
Non-WT isolates for non-A. fumigatus vary between 5–13%
Clear relationship between non-WT triazole MICs for A. fumigatus and a poor lack of response to therapy
In some cases, single or multiple point mutations are responsible for an increased level of cyp51A expression
In case of posaconazole, plasma concentrations seem to be most important
Voriconazole/Posaconazole
A. fumigatus 2/0.25 1/0.5
A. ﬂavus IE/IE 1/0.25
A. terreus IE/0.12 1/0.25
A. niger IE 2/0.5
Echinocandins MEC Limited data are available
Breakthrough infections occur, overexpression in the absence of FKS gene mutation
Usually MECs 1.0 lg/mL, non-WT MICs are species dependent, highest for A. nidulans
Caspofungin
A. fumigatus ND 0.5
A. ﬂavus ND 0.25
A. terreus ND 0.25
A. niger ND 0.25
IE, insufﬁcient evidence; ND, no data yet available; MEC: minimum effective concentrations for testing echinocandins; CLSI, Clinical and Laboratory Standards Institute; and
EUCAST, European Committee on Antibiotic Susceptibility Testing.
Data [4,7,10,30–32].
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Conclusion
Epidemiological cut-off values deﬁne the upper limit of
wild-type MIC distributions showing strains with no acquired
resistance mechanisms, CBPs are used to indicate isolates that
are likely to respond to treatment with a given antifungal agent
administered at the approved dosing regimen. in vitro suscep-
tibility testing discriminate non-WT from WT strains of most
Aspergillus species complex when testing amphotericin B and
the triazoles. Either poor response to therapy or failure has
been linked to non-WT or high MICs of amphotericin B and
especially itraconazole and voriconazole in isolated aspergillo-
sis cases. Less information is available for the echinocandins. As
ECOFFs are species speciﬁc, identiﬁcation of the infecting
isolate to the species level is helpful in selecting an antifungal
agent.
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